It’s been a slow week, so it’s probably useful for me to pause for a moment and think about what’s coming. Here’s a short list of the milestones that I’m
There are two ways to think about this report from I-MAK that calculated that just four medicines -- Humira, Rituxan, Avastin and Lantus -- made more than $150 billion in